PubRank

Louis L Pisters

Author PubWeight™ 121.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008 18.60
2 Prediction of erectile function following treatment for prostate cancer. JAMA 2011 3.92
3 Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 2003 2.41
4 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 2009 2.34
5 Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 2009 2.18
6 Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2008 2.16
7 Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 2002 1.95
8 Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 2004 1.91
9 Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 2006 1.70
10 Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007 1.69
11 Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 2008 1.68
12 Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007 1.56
13 Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol 2008 1.54
14 Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 2007 1.49
15 Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 2007 1.49
16 Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002 1.47
17 Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int 2010 1.46
18 Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int 2013 1.44
19 Modified suprapubic prostatectomy without irrigation is safe. Urology 2009 1.43
20 Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007 1.42
21 Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 2003 1.41
22 Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 2009 1.41
23 Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008 1.40
24 Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Can J Urol 2016 1.39
25 PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 2014 1.39
26 Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004 1.39
27 The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006 1.36
28 The growing teratoma syndrome: Current review of the literature. Indian J Urol 2009 1.32
29 Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer 2006 1.27
30 Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 2006 1.27
31 An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007 1.25
32 Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 2006 1.20
33 Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol 2012 1.19
34 Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003 1.17
35 Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 2009 1.08
36 Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 2003 1.06
37 The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 2002 1.04
38 Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002 1.03
39 Surgical management of lymph-node-positive prostate cancer: improves symptomatic control. BJU Int 2010 1.03
40 Port-site hernias occurring after the use of bladeless radially expanding trocars. Urology 2009 1.03
41 Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol 2005 1.02
42 Pretreatment semen parameters in men with cancer. J Urol 2008 1.02
43 Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 2011 1.01
44 Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 2003 1.01
45 Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 2004 0.97
46 Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 2006 0.97
47 Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 2008 0.94
48 Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002 0.94
49 Management of urethral recurrence after orthotopic urinary diversion. BJU Int 2009 0.94
50 A simplified protocol for evaluating and monitoring urethral stricture patients minimizes cost without compromising patient outcome. Trop Doct 2010 0.93
51 Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol 2012 0.93
52 Prostate cancer invading the rectum: a clinicopathological study of 18 cases. Pathology 2009 0.93
53 Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 2002 0.92
54 Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int 2013 0.92
55 Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006 0.90
56 Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 2006 0.90
57 Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 2002 0.90
58 Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 2005 0.89
59 Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 2005 0.89
60 Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 2005 0.89
61 Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol 2003 0.89
62 Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 2007 0.88
63 Salvage surgery for locally recurrent prostate cancer after radiation therapy: tricks of the trade. Urol Oncol 2007 0.88
64 Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol 2009 0.88
65 Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 2004 0.87
66 Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. World J Urol 2012 0.87
67 Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going? Urol Oncol 2007 0.87
68 Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 2006 0.86
69 Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 2004 0.85
70 Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol 2005 0.85
71 Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 2012 0.84
72 Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology 2006 0.84
73 Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol 2010 0.84
74 The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2009 0.84
75 Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 2006 0.84
76 Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol 2010 0.84
77 Incomplete glandular ablation after salvage cryotherapy for recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003 0.81
78 A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int 2009 0.81
79 Longstanding hydrocele in adult Black Africans: Is preoperative scrotal ultrasound justified? Niger Med J 2011 0.79
80 Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 2008 0.79
81 Recurrent seminomas: clinical features and biologic implications. Urol Oncol 2010 0.79
82 Salvage therapy for radiorecurrent prostate cancer. Curr Probl Cancer 2008 0.78
83 A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int 2007 0.78
84 Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 2005 0.77
85 Treatment failure after primary and salvage therapy for prostate cancer. Cancer 2008 0.77
86 Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 2004 0.77
87 Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer? Urol Oncol 2007 0.77
88 Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic testicular nonseminomatous germ cell tumor. Urology 2002 0.77
89 Histological changes in prostate biopsies after salvage cryotherapy: effect of chronology and the method of biopsy. BJU Int 2006 0.76
90 An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer. Urology 2007 0.75
91 Modifying and increasing day-case procedures to solve local problems: Experience of a urology unit. Niger Med J 2012 0.75
92 Considerations for patient selection for focal therapy. Ther Adv Urol 2013 0.75
93 Variant prostate carcinoma and elevated serum CA-125. Can J Urol 2014 0.75
94 Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 2007 0.75
95 Long-term outcomes and patient satisfaction of continent catheterizable limb and augmentation cystoplasty simultaneous with salvage prostatectomy. Neurourol Urodyn 2010 0.75
96 Surgery for locally advanced disease. Curr Urol Rep 2006 0.75
97 Metastatic penile cancer in a young Caucasian male: impact of delayed diagnosis. Urol Oncol 2005 0.75
98 Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 2003 0.75
99 Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer 2005 0.75
100 Monti reconstruction in patients with complex vesicovaginal fistula. Can J Urol 2010 0.75
101 Magnetic resonance imaging assessment of a convective therapy delivery paradigm in a canine prostate model. J Magn Reson Imaging 2007 0.75
102 Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence. BJU Int 2006 0.75
103 Cryotherapy for prostate cancer. Expert Rev Anticancer Ther 2003 0.75
104 Robotic Total Pelvic Exenteration. Dis Colon Rectum 2017 0.75
105 Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol 2007 0.75
106 Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history? Int Braz J Urol 2010 0.75
107 [Palliative surgery for locally advanced prostate cancer]. Harefuah 2009 0.75
108 Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology 2007 0.75
109 Effect of modified suprapubic prostatectomy for benign prostatic hyperplasia on postoperative hemoglobin levels. Can J Urol 2010 0.75